Evidence map›Paper›PMID 32637960›Full record

ArticlebioRxiv : the preprint server for biology2020

A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic.

Maria Alimova, Eriene-Heidi Sidhom, Abhigyan Satyam, Moran Dvela-Levitt, Michelle Melanson, Brian T Chamberlain, Seth L Alper, Jean Santos, Juan Gutierrez, Ayshwarya Subramanian and 25 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 13 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 4 institutions in 2 countries.

Maria AlimovaThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Eriene-Heidi SidhomThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Abhigyan SatyamBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
Moran Dvela-LevittThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Michelle MelansonThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Brian T ChamberlainThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Seth L AlperThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Jean SantosThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Juan GutierrezThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Ayshwarya SubramanianThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Elizabeth GrinkevichThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Estefania Reyes BricioThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Choah KimThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Abbe ClarkThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Andrew WattsThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Rebecca ThompsonThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Jamie MarshallThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Juan Lorenzo PabloThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Juliana CoraorThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Julie RoignotThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Katherine A VernonThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Keith KellerThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Alissa CampbellThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Maheswarareddy EmaniThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Matthew RacetteThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Silvana Bazua-ValentiThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Valeria PadovanoThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Astrid WeinsBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Stephen P McAdooDepartment of Immunology and Inflammation, Imperial College, Hammersmith Hospital, London, UK.
Frederick W K TamDepartment of Immunology and Inflammation, Imperial College, Hammersmith Hospital, London, UK.
Lucienne RoncoThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Florence WagnerThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
George C TsokosBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
Jillian L ShawThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Anna GrekaThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Broad Institute · USBeth Israel Deaconess Medical Center · USHammersmith Hospital · GBBrigham and Women's Hospital · US

Funding

T cells in LupusR01AI148161 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TSOKOS, GEORGE C · 2020 to 2024
$2.2M
NIAID NIH HHS R01 AI148161
6 · The paper itself

Abstract

Drug repurposing is the only method capable of delivering treatments on the shortened time-scale required for patients afflicted with lung disease arising from SARS-CoV-2 infection. Mucin-1 (MUC1), a membrane-bound molecule expressed on the apical surfaces of most mucosal epithelial cells, is a biochemical marker whose elevated levels predict the development of acute lung injury (ALI) and respiratory distress syndrome (ARDS), and correlate with poor clinical outcomes. In response to the pandemic spread of SARS-CoV-2, we took advantage of a high content screen of 3,713 compounds at different stages of clinical development to identify FDA-approved compounds that reduce MUC1 protein abundance. Our screen identified Fostamatinib (R788), an inhibitor of spleen tyrosine kinase (SYK) approved for the treatment of chronic immune thrombocytopenia, as a repurposing candidate for the treatment of ALI.

Identifiers

PMID32637960
PMCPMC7337390
OpenAlexW3038456204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.